Israeli biomedical company BioCell, which develops treatments for cancer, reports positive preliminary findings in trials conducted with BC-819. The drug, developed for treatment of pancreatic cancer, has registered a 66 percent success rate in stopping the diseases progress and even reducing tumor size. The trial’s final results will be published in the beginning of 2013.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

People With Autism Experience Higher Intensity Pain
January 30, 2023

Israeli Innovation At New Bahraini Hospital
January 30, 2023

US Car Giant Signs Up For AI Vehicle Inspections
January 29, 2023

Considerate Partners Are Less Likely To Cheat
January 29, 2023
Facebook comments